多种生物标志物的风险评分准确预测急性冠状动脉综合征患者的长期预后
Zhi-Yong Zhang1, Xin-Yu Wang1, Cong-Cong Hou2
1Heart-center of Beijing Chao-Yang Hospital, Capital Medical University, Beijing Key Laboratory of Hypertension, Beijing, China.
新的CB-ACS风险评分有效预测急性冠状动脉综合征 (ACS) 患者的长期心血管事件. 这种生物标志物综合评分优于现有的GRACE 2.0模型.
科学领域:
- 心脏病学
- 生物标志物
- 风险预测
背景情况:
- 使用生物标志物对急性冠状动脉综合征 (ACS) 的长期风险预测有限.
- 现有的风险评分可能无法完全捕捉到ACS预后的复杂性.
研究的目的:
- 开发和验证用于预测ACS患者长期心血管事件的新风险评分.
- 整合临床信息和血生物标志物以提高风险分层.
主要方法:
- 使用了2729名ACS患者的队列,其中1910名在开发和819名在验证队列中.
- 考克斯回归模型确定了关键预测因子,包括NT-proBNP,D-dimer,GDF-15,PAD,Fibrinogen,STEMI和LVEF.
- 结合临床生物标志物 (CB-ACS) 评分得出并得到验证.
主要成果:
- 开发队列中的C指数为0. 79,验证队列中的C指数为0. 77.
- 这一分数准确地预测了十年内心血管死亡,心肌梗塞和全因死亡的风险.
- 通过CB-ACS比GRACE 2.0和ABC-ACS等已知风险得分更好.
结论:
- 在ACS患者中,CB-ACS风险评分是预测长期心血管事件的有价值工具.
- 与目前的临床风险分数相比,这种综合方法提供了更好的风险分层.
更多相关视频
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
08:51Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
Published on: September 20, 2024
相关概念视频
Acute Coronary Syndrome III: Diagnostic Studies
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Acute Coronary Syndrome I: Introduction
